 | Up a level |
Esposito, Roberta; Lanzos, Andrés; Uroda, Tina; Ramnarayanan, Sunandini; Büchi, Isabel; Polidori, Taisia; Guillen-Ramirez, Hugo; Mihaljevic, Ante; Merlin, Bernard Mefi; Mela, Lia; Zoni, Eugenio; Hovhannisyan, Lusine; McCluggage, Finn; Medo, Matúš; Basile, Giulia; Meise, Dominik F; Zwyssig, Sandra; Wenger, Corina; Schwarz, Kyriakos; Vancura, Adrienne; ... (2023). Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness. Nature communications, 14(1), p. 5463. Nature Publishing Group 10.1038/s41467-023-41288-5
Naef, Pascal; Radpour, Ramin; Jaeger-Ruckstuhl, Carla A; Bodmer, Nils; Baerlocher, Gabriela M; Doehner, Hartmut; Doehner, Konstanze; Riether, Carsten; Ochsenbein, Adrian F (2023). IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways. Science signaling, 16(800), eadd7705. 10.1126/scisignal.add7705
Pabst, Thomas; Vey, Norbert; Adès, Lionel; Bacher, Ulrike; Bargetzi, Mario; Fung, Samson; Gaidano, Gianluca; Gandini, Domenica; Hultberg, Anna; Johnson, Amy; Ma, Xuewen; Müller, Rouven; Nottage, Kerri; Papayannidis, Cristina; Recher, Christian; Riether, Carsten; Shah, Priya; Tryon, Jeffrey; Xiu, Liang and Ochsenbein, Adrian F (2023). Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica - the hematology journal, 108(7), pp. 1793-1802. Ferrata-Storti Foundation 10.3324/haematol.2022.281563
Yang, Haitang; Gao, Yanyun; Xu, Duo; Xu, Ke; Shun-Qing, Liang; Yang, Zhang; Scherz, Amina; Hall, Sean R R; Forster, Stefan; Berezowska, Sabina; Yao, Feng; Ochsenbein, Adrian F; Marti, Thomas M; Kocher, Gregor J; Schmid, Ralph A; Dorn, Patrick; Peng, Ren-Wang (2023). MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell death discovery, 9(1), p. 55. Nature 10.1038/s41420-023-01307-2
Forster, Stefan; Radpour, Ramin; Ochsenbein, Adrian F (2023). Molecular and immunological mechanisms of clonal evolution in multiple myeloma. Frontiers in immunology, 14(1243997), p. 1243997. Frontiers Research Foundation 10.3389/fimmu.2023.1243997
Bührer, Elias D; Amrein, Michael A; Forster, Stefan; Isringhausen, Stephan; Schürch, Christian M; Bhate, Salil S; Brodie, Tess; Zindel, Joel; Stroka, Deborah; Al Sayed, Mohamad; Nombela-Arrieta, César; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian F (2022). Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance. Leukemia, 36(11), pp. 2634-2646. Springer Nature 10.1038/s41375-022-01682-2
Esposito, Roberta; Polidori, Taisia; Meise, Dominik F; Pulido-Quetglas, Carlos; Chouvardas, Panagiotis; Forster, Stefan; Schaerer, Paulina; Kobel, Andrea; Schlatter, Juliette; Kerkhof, Erik; Roemmele, Michaela; Rice, Emily S.; Zhu, Lina; Lanzós, Andrés; Guillen-Ramirez, Hugo A; Basile, Giulia; Carrozzo, Irene; Vancura, Adrienne; Ullrich, Sebastian; Andrades, Alvaro; ... (2022). Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. Cell genomics, 2(9), p. 100171. Elsevier 10.1016/j.xgen.2022.100171
Haas, Quentin; Markov, Nikita; Muerner, Lukas; Rubino, Viviana; Benjak, Andrej; Haubitz, Monika; Baerlocher, Gabriela M; Ng, Charlotte K Y; Münz, Christian; Riether, Carsten; Ochsenbein, Adrian F; Simon, Hans-Uwe; von Gunten, Stephan (2022). Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. Frontiers in immunology, 13, p. 996746. Frontiers Research Foundation 10.3389/fimmu.2022.996746
Rothschild, Sacha I; Zippelius, Alfred; Eboulet, Eric I; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Ochsenbein, Adrian F; Janthur, Wolf-Dieter; Waibel, Christine; Mach, Nicolas; ... (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of clinical oncology, 39(26), pp. 2872-2880. American Society of Clinical Oncology 10.1200/JCO.21.00276
Ochsenbein, Adrian F; Schubert, Adrian D; Vassella, Erik; Mariani, Luigi (2011). Quantitative analysis of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. Journal of neuro-oncology, 103(2), pp. 343-51. Boston, Mass.: Springer US; http://www.springer-ny.com 10.1007/s11060-010-0395-2
Stupp, Roger; Hegi, Monika E; Neyns, Bart; Goldbrunner, Roland; Schlegel, Uwe; Clement, Paul M J; Grabenbauer, Gerhard G; Ochsenbein, Adrian F; Simon, Matthias; Dietrich, Pierre-Yves; Pietsch, Torsten; Hicking, Christine; Tonn, Joerg-Christian; Diserens, Annie-Claire; Pica, Alessia; Hermisson, Mirjam; Krueger, Stefan; Picard, Martin; Weller, Michael (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of clinical oncology, 28(16), pp. 2712-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2009.26.6650
Mumprecht, Sabine Barbara; Schürch, Christian; Schwaller, Juerg; Solenthaler, Max; Ochsenbein, Adrian F (2009). Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114(8), pp. 1528-1536. Washington, D.C.: American Society of Hematology 10.1182/blood-2008-09-179697
Mumprecht, Sabine; Claus, Christina; Schürch, Christian; Pavelic, Viktor; Matter, Matthias S; Ochsenbein, Adrian F (2009). Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood, 113(19), pp. 4681-9. Washington, D.C.: American Society of Hematology 10.1182/blood-2008-05-156471
Pavelic, Viktor; Matter, Matthias S; Mumprecht, Sabine; Breyer, Isabel; Ochsenbein, Adrian F (2009). CTL induction by cross-priming is restricted to immunodominant epitopes. European journal of immunology, 39(3), pp. 704-16. Weinheim: Wiley-VCH 10.1002/eji.200838901
Matter, Matthias S; Ochsenbein, Adrian F (2008). Natural antibodies target virus-antibody complexes to organized lymphoid tissue. Autoimmunity reviews, 7(6), pp. 480-6. Amsterdam: Elsevier 10.1016/j.autrev.2008.03.018
Ho, Cheryl; Ochsenbein, Adrian F; Gautschi, Oliver; Davies, Angela M (2008). Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clinical lung cancer, 9 Suppl 1, S20-S27. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.004
Matter, Matthias S; Claus, Christina; Ochsenbein, Adrian F (2008). CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression. European journal of immunology, 38(7), pp. 1847-56. Weinheim: Wiley-VCH 10.1002/eji.200737824
Matter, Matthias; Pavelic, Viktor; Pinschewer, Daniel D; Mumprecht, Sabine; Eschli, Bruno; Giroglou, Tsanan; von Laer, Dorothee; Ochsenbein, Adrian F (2007). Decreased tumor surveillance after adoptive T-cell therapy. Cancer research, 67(15), pp. 7467-76. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-06-4372
Cresto, Nicola; Barth, Alain; Arnold, Marlene; Weimann, Rosemarie; Gschossmann, Jürgen; Ochsenbein, Adrian F; Kolotas, Christos; Peter, Hans-Jakob; Schiemann, Uwe (2007). Aussergewöhnliche Manifestation eines Magenkarzinoms mit Meningeosis carcinomatosa und spinaler Metastase. Medizinische Klinik, 102(3), pp. 255-8. München: Urban & Vogel 10.1007/s00063-007-1030-7
Matter, Matthias; Odermatt, Bernhard; Yagita, Hideo; Nuoffer, Jean-Marc; Ochsenbein, Adrian F (2006). Elimination of chronic viral infection by blocking CD27 signaling. Journal of experimental medicine, 203(9), pp. 2145-55. New York, N.Y.: Rockefeller University Press 10.1084/jcm.20060651
Mumprecht, Sabine; Matter, Matthias; Pavelic, Viktor; Ochsenbein, Adrian F (2006). Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood, 108(10), pp. 3406-13. Washington, D.C.: American Society of Hematology 10.1182/blood-2006-04-018705
